购物车
- 全部删除
- 您的购物车当前为空
Azeliragon (TTP488) 是一种生物可利用的、可穿过血脑屏障 (BBB)的晚期糖基化终产物 (RAGE) 受体抑制剂,可缓解轻度阿尔茨海默病 (AD) 的发展。
Azeliragon (TTP488) 是一种生物可利用的、可穿过血脑屏障 (BBB)的晚期糖基化终产物 (RAGE) 受体抑制剂,可缓解轻度阿尔茨海默病 (AD) 的发展。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 387 | 现货 | |
2 mg | ¥ 559 | 现货 | |
5 mg | ¥ 828 | 现货 | |
10 mg | ¥ 1,270 | 现货 | |
25 mg | ¥ 2,520 | 现货 | |
50 mg | ¥ 3,830 | 现货 | |
100 mg | ¥ 5,490 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 972 | 现货 |
产品描述 | Azeliragon (TTP488) is an antagonist at the Receptor for Advanced Glycation End products; is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer_acute_s disease (AD). |
激酶实验 | Recombinant Kinase Assays [1]: The ability of AZD5438 to inhibit cdk activity is examined using a scintillation proximity assay with recombinant cdk-cyclin complexes of cyclin-Ecdk2, cdk2-cyclin A, cdk4-cyclin D, and recombinant retinoblastoma substrate (amino acids 792-928) or cdk1-cyclin B1 with a peptide substrate derived from the in vitro p34cdc2 phosphorylation site of histone H1 (biotin-X-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu). The activity of AZD5438 against recombinant cdk5/p25 (at 2 μM ATP) is determined in a scintillation proximity assay-based assay using peptide substrate (AKKPKTPKKAKKLOH). Inhibition of glycogen synthase kinase 3β activity is determined with scintillation proximity assay based on the use of human purified glycogen synthase kinase 3βenzyme and eukaryotic initiation factor 2B substrate (at 1 μM ATP). AZD5438 is screened against active recombinant human cdk6-cyclin D3, cdk7-cyclin H/MAT1 (cdk activating kinase complex), and cdk9-cyclin T using the kinase selectivity screening service. |
别名 | TTP488, 阿齐瑞格 |
分子量 | 532.12 |
分子式 | C32H38ClN3O2 |
CAS No. | 603148-36-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 11 mg/mL (20.67 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.